Trial Profile
Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Relacorilant (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
- 18 Apr 2019 According to a Corcept Therapeutics media release, the data will be presented at the 2019 American Association of Clinical Endocrinologists 28th Annual Congress
- 18 Mar 2019 Results (n=2) presented at the 101st Annual Meeting of the Endocrine Society
- 16 Nov 2018 This trial has been completed in Hungary on-2018-09-24, according to European Clinical Trials Database.